VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
NEUP
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
NEUPNeuphoria Therapeutics Inc.
$2.28$12M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksNEUPBalance Sheet

Neuphoria Therapeutics Inc. (NEUP) Balance Sheet

28Y historyFree accessUpdated daily

The company's capital structure appears vulnerable, with $8.8 million in goodwill representing a significant portion of the $34.8 million in total assets as of 2026Q3.

Income StatementBalance SheetCash FlowRatios

NEUP Balance Sheet

Annual statement

NEUP Balance Sheet

Neuphoria Therapeutics Inc. (NEUP) balance sheet — 28-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMJun'26Jun'25Jun'24Jun'23Jun'22Jun'21Jun'20Jun'19Jun'18Jun'17Jun'16Jun'15Jun'14Jun'13Jun'12Jun'11Jun'10Jun'09Jun'08Jun'07Jun'06Jun'05Jun'04Jun'03Jun'02Jun'01Jun'00Jun'99
Total Current Assets19.6M21.07B22.85M13.19M8.87M41.81M23.24M5.73M17.6M26.39M41.86M43.38M29.05M37.21M28.03M22.25M26.6M11.81M4.75M8.47M11.84M3.83M7.2M6.27M4.18M4.97M5.08M2.8M142.19K
Cash & Short-Term Investments18.74M21.59M21.59M12.61M8.06M33.56M21.41M3.15M10.18M18.72M33.37M34.35M20.79M9.89M20.49M17.74M17.16M10.72M3.84M6.01M10.87M3.51M6.87M6.08M4.09M4.84M724312.12K57.41K
Cash Only18.74M21.59M21.59M12.61M8.06M33.56M21.41M3.15M9.79M18.31M32.95M33.94M20.37M9.89M20.49M17.74M17.16M10.72M3.84M6.01M10.87M3.51M6.87M6.08M4.09M4.84M724312.12K57.41K
Short-Term Investments00000000385.19K404.02K422.65K410.73K421.85K0000000000000000
Accounts Receivable700.22K813.43K11.95K126.88K283.62K6.78M192.88K40.74K621.02K523.5K7.6M8.22M815.84K19.53M644.04K421.04K9.03M719.93K625.82K2.21M287.63K179.84K107.59K94.64K18.51K55.92K43.22K43.54K0
Days Sales Outstanding328.65252.860.28--6.46K75.9463.7830.6516102.22575.1158.57395.48157.33133.35968.78103.2978.39750.4151.45135.59174.26-9.7522.4926.33--
Inventory00000000465.4K360.02K327.16K327.73K314.39K78.54K89.91K138.45K45.58K96.1K98.78K76.02K84.27K33.27K23.69K000000
Days Inventory Outstanding--------145.184.93-------106.79130.24212.49171.96213.36------
Other Current Assets156.68K1.2B136.58K35100984.28K2.01M5.49M6.09M2.02K2496.22M7.31M6.42M3.59M102.61K22.3K5.97K36.69K502.74K25.9K6.74K39.34K22.77K56K5.03M2.44M84.78K
Total Non-Current Assets7.5M7.64B20.59M14.46M10.52M23.5M17.53M17.95M19.98M21.41M22.74M22.35M23.97M24.05M20.89M9.58M10.07M14.97M15.2M18.62M14.31M10.8M5.8M4.19M4.29M3.94M441.67K369.88K0
Property, Plant & Equipment00160.12K218.97K221.66K674.46K654.37K724.9K1.76M2.02M2.01M2.12M2.65M779.9K769.18K791.34K323.52K6.72M6.76M8.25M7.32M4.19M4.31M4.18M4.25M3.89M369.32K259.85K0
Fixed Asset Turnover--97.74x--0.57x1.42x0.04x4.21x5.92x13.49x2.46x1.92x23.11x1.94x1.46x10.52x0.38x0.43x0.13x0.09x0.12x0.05x-0.16x0.23x1.62x--
Goodwill3.53M3.5B13.13M8.69M5.79M12.87M9.32M8.84M8.94M9.16M9.42M7.95M8.04M8.93M4.7M5.27M5.5M4.38M4.15M4.93M1.8M1.62M1.49M000000
Intangible Assets3.98M4.14B7.3M5.47M4.08M9.84M7.47M8.08M9.02M9.95M11.01M12M12.98M14.33M15.43M3.45M4.25M3.88M4.29M5.44M5.18M5M5869.91K38.21K55.87K72.35K110.04K0
Long-Term Investments00078.83K52.52K0119K436.17K384K282.08K295.08K286.76K294.53K0000000000000000
Other Non-Current Assets000-7953118.99K-29.59K-136.47K-115.07K00000000000000000000
Total Assets27.11M28.71B43.44M27.65M19.39M65.3M40.77M23.68M37.58M47.8M64.61M65.72M53.02M61.25M48.93M31.83M36.67M26.78M19.95M27.09M26.14M14.63M13M10.46M8.47M8.92M5.53M3.17M142.19K
Asset Turnover0.04x0.00x0.36x--0.01x0.02x0.00x0.20x0.25x0.42x0.08x0.10x0.29x0.03x0.04x0.09x0.09x0.15x0.04x0.03x0.03x0.02x-0.08x0.10x0.11x--
Asset Growth %80%65990.33%57.11%42.57%-70.3%60.17%72.17%-36.99%-21.38%-26.02%-1.7%23.95%-13.44%25.2%53.71%-13.19%36.91%34.22%-26.34%3.62%78.69%12.53%24.28%23.5%-5.01%61.36%74.38%2128.83%-
Total Current Liabilities1.09M756.58M6.41M3.83M4.12M3.36M1.77M5.68M9.67M9.76M10.67M8.5M10.51M8.74M5.55M4.57M5.86M2.75M2.25M2.92M3.06M1.99M1.55M982.39K828.77K474.52K302.26K103.71K472.62K
Accounts Payable724.7K385.58K1.75M2.24M958.06K1.56M772.93K866.78K842.3K2.65M1.46M1.97M3.02M2.51M2.99M2.04M1.45M1.18M917.24K1.65M1.8M799.41K730.32K366.47K235.93K194.31K78.5K90.44K339.11K
Days Payables Outstanding414.47212.29965.761.24K520.7835.51166.88-25.3538.1122-------991.622.83K4.53K4.13K6.58K------
Short-Term Debt034.34K49.76K33.12K97.9K003.56M5.92M4.29M6.53M2.89M4.19M742.46K620.91K749.96K3.02M532.82K426.94K547.42K416.67K284.8K273.11K355.45K342.56K71.56K00133.51K
Deferred Revenue (Current)00000000158.09K64.17K14.99K49.15K57.8K3.08M34.17K18.61K51.06K59.83K84.24K230.91K93.13K161.6K118.81K34.71K13.79K68.79K37.22K00
Other Current Liabilities1.09M756.16M54.33K328.89K11.3K409.28K279.45K267.17K654.1K1.1M1.31M1.19M1.31M1.12M986.6K909.6K778.14K510.47K516.68K353.53K402.33K339.04K391.5K225.76K236.5K139.86K175.21K00
Current Ratio18.05x27.85x3.56x3.45x2.15x12.46x13.10x1.01x1.82x2.70x3.92x5.10x2.76x4.26x5.05x4.87x4.54x4.29x2.11x2.90x3.86x1.92x4.64x6.38x5.04x10.48x16.82x26.99x0.30x
Quick Ratio18.05x27.85x3.56x3.45x2.15x12.46x13.10x1.01x1.77x2.67x3.89x5.06x2.73x4.25x5.03x4.83x4.53x4.26x2.07x2.88x3.83x1.91x4.62x6.38x5.04x10.48x16.82x26.99x0.30x
Cash Conversion Cycle-85.82-------19.31-16.9485.14--------806.43-1.95K-4.17K-3.82K-6.19K------
Total Non-Current Liabilities2.55M3.35B8.15M6.33M2.92M5.04M3.23M9.28M15.52M25.58M22.85M25.53M17.99M10.32M5.59M752.23K138.53K2.39M2.61M3.57M3.82M4.52M3.31M3.23M3.12M2.82M25.52K43.12K33.38K
Long-Term Debt00000004.3M6.06M11.56M7.69M13.77M7.15M476.06K365.19K454.33K7.91K2.29M2.55M3.38M3.23M2.9M3.27M3.2M3.08M2.82M25.52K29.85K33.38K
Capital Lease Obligations000117.63K360.98K533.52K521.14K17.48K00000000000054.77K46.92K0000000
Deferred Tax Liabilities1.49M355.94M0963.54K1.11M1.8M1.38M1.51M2.06M2.21M3.67M3.78M4.32M4.09M000000431.23K1.5M0000000
Other Non-Current Liabilities2.23M3B8.15M5.25M1.64M2.71M1.33M3.45M7.4M11.81M11.49M7.99M6.53M5.76M5.22M297.9K130.62K102.56K59.98K190.86K105.19K76.26K36.23K34.96K33.69K0013.27K0
Total Liabilities3.63M4.11B14.57M10.16M4.74M8.4M5.01M14.97M25.18M35.34M33.52M34.04M28.51M19.06M11.14M5.32M6M5.14M4.87M6.49M6.89M6.51M4.86M4.22M3.95M3.29M327.78K146.83K506K
Total Debt034.34K226.49K272.74K582.35K693.55K652.04K8.41M11.98M15.85M14.22M16.66M11.33M1.22M986.1K1.2M3.03M2.82M2.98M3.93M3.75M3.25M3.54M3.55M3.43M2.89M25.52K29.85K166.89K
Net Debt-18.74M-21.56M-21.37M-12.34M-7.8M-32.87M-20.76M5.26M2.18M-2.47M-18.72M-17.28M-9.04M-8.67M-19.5M-16.54M-14.13M-7.9M-858.15K-2.08M-7.13M-257.88K-3.32M-2.53M-664.69K-1.95M24.79K-282.27K109.48K
Debt / Equity0.00x0.00x0.01x0.02x0.04x0.01x0.02x0.96x0.97x1.27x0.46x0.53x0.46x0.03x0.03x0.05x0.10x0.13x0.20x0.19x0.19x0.40x0.44x0.57x0.76x0.51x0.00x0.01x-
Debt / EBITDA-0.00x----------------------------
Net Debt / EBITDA2.68x----------------------------
Interest Coverage------1185.95x-5.38x-2.35x-7.64x-15.91x-3.63x-8.15x-19.00x7.48x-126.41x-50.65x-32.04x-32.14x-23.37x-15.41x-24.90x-15.89x-13.58x-10.25x-14.02x-47.22x--305.82x-66.41x
Total Equity23.47M24.6B28.87M17.49M14.65M56.91M35.76M8.71M12.39M12.46M31.09M31.69M24.52M42.2M37.79M26.51M30.67M21.64M15.09M20.6M19.25M8.12M8.14M6.24M4.52M5.62M5.2M3.02M-363.81K
Equity Growth %202.03%85102.23%65.08%19.37%-74.25%59.13%310.39%-29.7%-0.5%-59.93%-1.9%29.25%-41.9%11.67%42.57%-13.59%41.72%43.45%-26.75%6.98%137.02%-0.25%30.41%38%-19.54%8.18%72%930.72%-
Book Value per Share4.345596.0017.790.120.120.500.550.190.290.310.770.830.701.211.210.921.140.860.751.101.280.631.511.541.351.842.192.46-1.45
Total Shareholders' Equity23.47M24.6B28.87M17.49M14.65M56.91M35.76M8.71M12.39M12.46M31.09M31.69M24.52M42.2M37.79M26.51M30.67M21.64M15.09M20.6M19.25M8.12M8.14M6.24M4.52M5.62M5.2M3.02M-363.81K
Common Stock5454K29110217.67M142.9M101.8M101.51M99.33M103.38M100.36M85.9M105.19M101.58M89.89M93.72M63.84M48.4M53.67M44.81M28.23M25M18.29M13.72M10.75M8.07M4.42M251K
Retained Earnings-193.22M-191.8B-270.98M-177.98M-108.16M-173.29M-115.74M-102.3M-98.65M-96.49M-83.14M-77.05M-66.4M-65.54M-66.46M-64.29M-63.79M-44.9M-36.01M-36.13M-27.97M-20.43M-16.67M-12.04M-9.2M-5.13M-2.87M-1.4M-614.81K
Treasury Stock00000000000000000000000000000
Accumulated OCI-1.84M-2.06B-4.32M-3.01M3.2M12.52M8.6M9.22M9.54M9.62M10.85M8.38M5.02M2.56M2.66M908K742.64K2.71M2.7M3.05M2.41M322.13K-195.22K000000
Minority Interest00000000000000000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Clinical Milestone Funding Dependency

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Capital Base Subject to Volatility

As reported in financial statements, Neuphoria Therapeutics' total assets fluctuated significantly from $18.2 million in 2025Q2 to $43.4 million by 2025Q4, reflecting an unstable capital trajectory that appears heavily dependent on the timing of non-recurring licensing inflows rather than organic growth in core business assets.

The erratic movement in total assets suggests that the company's balance sheet is currently a reflection of transactional milestones rather than a steady accumulation of productive capital. Investors should monitor whether this volatility stabilizes as the company moves deeper into clinical development, as the current pattern indicates a high sensitivity to external funding events.

Liquidity Buffers Mask Operational Burn

Based on the reported figures, the company's current ratio reached 14.31 in 2026Q3, yet this high liquidity metric appears misleading given the consistent quarterly cash burn and the absence of recurring revenue streams to support ongoing research and development activities over the long term.

While the current ratio suggests a strong short-term buffer, the underlying cash position of $19.4 million in 2026Q3 is rapidly depleting relative to the company's high fixed-cost structure. This liquidity profile warrants caution, as it may provide a false sense of security regarding the company's ability to fund multi-year clinical trials without further dilutive financing.

Equity Quality Diluted by Compensation

According to recent SEC filings, the company's equity base has been significantly impacted by large-scale stock-based compensation, which reached $163.7 million in 2025Q4, effectively obscuring the true economic value of shareholder capital and complicating the assessment of management's long-term incentive alignment with external investors.

The massive swings in retained earnings, which dropped to -$271.0 million in 2025Q4, suggest that the equity structure is being heavily utilized to manage talent costs rather than reflecting retained operational success. This reliance on equity-based incentives may indicate that management is prioritizing aggressive growth at the expense of long-term shareholder dilution.

Goodwill Impairment Risk Remains Elevated

As disclosed in the balance sheet data, the company carries $8.8 million in goodwill as of 2026Q3, a figure that represents a substantial portion of total assets and poses a significant risk of future impairment if clinical trial results fail to validate the underlying intellectual property.

The presence of significant intangible assets on a pre-revenue balance sheet suggests that the company's valuation is highly sensitive to subjective assessments of its clinical pipeline. If the lead neuropsychiatric candidates do not meet primary endpoints, the resulting goodwill write-down could severely impair the company's net asset value and further weaken its financial position.

NEUP — Frequently Asked Questions

Quick answers to the most common questions about buying NEUP stock.

What are the total assets of Neuphoria Therapeutics Inc. (NEUP)?

As of 2026, Neuphoria Therapeutics Inc. (NEUP) had total assets of $28.71B including $21.07B in current assets.

How much debt does Neuphoria Therapeutics Inc. (NEUP) have?

Neuphoria Therapeutics Inc. (NEUP) carries total debt of $0.0M, offset by $21.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Neuphoria Therapeutics Inc.?

Neuphoria Therapeutics Inc. (NEUP) has total shareholders' equity (book value) of $24.60B ($5596.00 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Neuphoria Therapeutics Inc.'s current ratio and liquidity?

Neuphoria Therapeutics Inc. (NEUP) reported a current ratio of 27.85x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.